Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Instructions to Expand Your Smash 1500's Presentation: Tips and Deceives - 2Changing Negative Cash Mentalities: Enabling Your Monetary Excursion
- 3The Most Vital Crossroads in Olympic History
- 4Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- 510 Demonstrated Systems to Develop Your Internet based Business
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- Understanding Various Sorts of Financial balances: An Extensive Outline
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- Vote In favor of Your Favored Kind Of Vegetable
- Mystery foot suggests a second early human relative lived alongside Lucy
- Mossad unveils network of Hamas terror infrastructure across Europe
- The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch
- Share your number one city visit transport that leaves a mark on the world wake up!
